Patents by Inventor Pascal Stein

Pascal Stein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-CD19 antibodies with reduced immunogenicity
    Publication number: 20070154473
    Abstract: Anti-CD19 B4 antibodies with modified variable regions are disclosed. The modified anti-CD19 variable region polypeptides have alterations to one or more framework regions or complementarity determining regions of the heavy chain variable region or light chain variable region, thereby to reduce a T-cell response.
    Type: Application
    Filed: December 29, 2006
    Publication date: July 5, 2007
    Applicant: Merck Patent GmbH
    Inventors: Michael Super, Jonathan Davis, Pascal Stein
  • Interleukin-12p40 variants with improved stability
    Publication number: 20070154453
    Abstract: Modified interleukin-12 (IL-12) p40 polypeptides are disclosed. The modified polypeptides have alterations in the IL-12p40 subunit to eliminate the protease site between positions Lys260 and Arg261. The modified IL-12p40 polypeptides according to the invention have improved stability compared to wild-type mature human IL-12p40 polypeptides.
    Type: Application
    Filed: December 29, 2006
    Publication date: July 5, 2007
    Applicant: Merck Patent GmbH
    Inventors: Gordon Webster, Suzanne McKenzie, Kin-Ming Lo, Pascal Stein
  • Compositions and methods for treating tumors presenting survivin antigens
    Publication number: 20070104689
    Abstract: The present invention provides compositions and methods that elicit an immune response against diseased cells. In particular, the present invention provides compositions and methods for the presentation of a peptide related to survivin on antigen-presenting cells. Presentation of the peptide leads to an immune response in a mammal against cells such as tumor cells overexpressing survivin.
    Type: Application
    Filed: September 26, 2006
    Publication date: May 10, 2007
    Applicant: Merck Patent GmbH
    Inventors: Stephen Gillies, Thore Hettmann, Pascal Stein, Stephan Klinz
  • IL-2 fusion proteins with modulated selectivity
    Publication number: 20070036752
    Abstract: The invention provides cytokine fusion proteins with an increased therapeutic index, and methods to increase the therapeutic index of such fusion proteins. The fusion proteins of the invention are able to bind to more than one type of cytokine receptor expressed on cells and also bind to more than one cell type. In addition, the fusion proteins of the invention exhibit a longer circulating half-life in a patient's body than the corresponding naturally occurring cytokine.
    Type: Application
    Filed: October 16, 2006
    Publication date: February 15, 2007
    Applicant: EMD Lexigen Research Center Corp.
    Inventors: Stephen Gillies, Pascal Stein, Kin-Ming Lo